The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Interaction between Human Prion Protein and Amyloid-β (Aβ) Oligomers
Open accessAbstract
Soluble oligomers of Abeta42 peptide are believed to play a major role in the pathogenesis of Alzheimer disease (AD). It was recently found that at least some of the neurotoxic effects of these oligomers may be mediated by specific binding to the prion protein, PrP(C), on the cell surface (Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., and Strittmatter, S. M. (2009) Nature 457, 1128-1132). Here we characterized the interaction between synthetic Abeta42 oligomers and the recombinant human prion protein (PrP) using two biophysical techniques: site-directed spin labeling and surface plasmon resonance. Our data indicate that this binding is highly specific for a particular conformation adopted by the peptide in soluble oligomeric species. The binding appears to be essentially identical for the Met(129) and Val(129) polymorphic forms of human PrP, suggesting that the role of PrP codon 129 polymorphism as a risk factor in AD is due to factors unrelated to the interaction with Abeta oligomers. It was also found that in addition to the previously identified approximately 95-110 segment, the second region of critical importance for the interaction with Abeta42 oligomers is a cluster of basic residues at the extreme N terminus of PrP (residues 23-27). The deletion of any of these segments results in a major loss of the binding function, indicating that these two regions likely act in concert to provide a high affinity binding site for Abeta42 oligomers. This insight may help explain the interplay between the postulated protective and pathogenic roles of PrP in AD and may contribute to the development of novel therapeutic strategies as well.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Prusiner, S. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13363 · Cited by 5,373
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Pathways towards and Away from Alzheimer’s Disease
Mattson, M. P. (2004) · Nature · doi:10.1038/nature02621 · Cited by 3,052
A Century of Alzheimer's Disease
Goedert, M., & Spillantini, M. G. (2006) · Science · doi:10.1126/science.1132814 · Cited by 2,098
Aβ Oligomers – a decade of discovery
Walsh, D. M., & Selkoe, D. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04426.x · Cited by 1,938
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857
Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers
Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., & Strittmatter, S. M. (2009) · Nature · doi:10.1038/nature07761 · Cited by 1,560
NMR solution structure of the human prion protein
Zahn, R., Liu, A., Lührs, T., Riek, R., von Schroetter, C., López García, F., Billeter, M., Calzolai, L., Wider, G., & Wüthrich, K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.1.145 · Cited by 1,098
In vitro characterization of conditions for amyloid-β peptide oligomerization and fibrillogenesis
Stine, W. B., Dahlgren, K. N., Krafft, G. A., & LaDu, M. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210207200 · Cited by 1,015
Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum?
Klein, W. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01749-5 · Cited by 989
Identifying conformational changes with site-directed spin labeling.
Hubbell, W. L., Cafiso, D. S., & Altenbach, C. (2000) · Nature Structural Biology · doi:10.1038/78956 · Cited by 915
Structural Classification of Toxic Amyloid Oligomers
Glabe, C. G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.r800016200 · Cited by 783
Physiology of the prion protein
Linden, R., Martins, V. R., Prado, M. A. M., Cammarota, M., Izquierdo, I., & Brentani, R. R. (2008) · Physiological Reviews · doi:10.1152/physrev.00007.2007 · Cited by 617
Amyloid β-Protein Assembly and Alzheimer Disease
Roychaudhuri, R., Yang, M., Hoshi, M. M., & Teplow, D. B. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.r800036200 · Cited by 615
Recent advances in site-directed spin labeling of proteins
Hubbell, W. L., Gross, A., Langen, R., & Lietzow, M. A. (1998) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(98)80158-9 · Cited by 550
Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein
Balducci, C., Beeg, M., Stravalaci, M., Bastone, A., Sclip, A., Biasini, E., Tapella, L., Colombo, L., Manzoni, C., Borsello, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911829107 · Cited by 466
The cellular prion protein (PrPC): Its physiological function and role in disease
Westergard, L., Christensen, H. M., & Harris, D. A. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2007.02.011 · Cited by 433
NEURODEGENERATIVE DISEASES: New Concepts of Pathogenesis and Their Therapeutic Implications
Skovronsky, D. M., Lee, V. M.-Y., & Trojanowski, J. Q. (2006) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100113 · Cited by 425
Alzheimer's disease and Aβ toxicity: from top to bottom
Small, D. H., Mok, S. S., & Bornstein, J. C. (2001) · Nature Reviews Neuroscience · doi:10.1038/35086072 · Cited by 394
Fibril Fragmentation Enhances Amyloid Cytotoxicity
Xue, W.-F., Hellewell, A. L., Gosal, W. S., Homans, S. W., Hewitt, E. W., & Radford, S. E. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.049809 · Cited by 384
Weissmann, C. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro1025 · Cited by 346
Molecular architecture of human prion protein amyloid: A parallel, in-register β-structure
Cobb, N. J., Sönnichsen, F. D., Mchaourab, H., & Surewicz, W. K. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706522104 · Cited by 326
Self-citationStructural Basis of Interdomain Communication in the Hsc70 Chaperone
Jiang, J., Prasad, K., Lafer, E. M., & Sousa, R. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.09.028 · Cited by 282
Cellular prion protein regulates β-secretase cleavage of the Alzheimer's amyloid precursor protein
Parkin, E. T., Watt, N. T., Hussain, I., Eckman, E. A., Eckman, C. B., Manson, J. C., Baybutt, H. N., Turner, A. J., & Hooper, N. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609621104 · Cited by 270
Fezoui, Y., Hartley, D. M., Harper, J. D., Khurana, R., Walsh, D. M., Condron, M. M., Selkoe, D. J., Lansbury, P. T., Fink, A. L., & Teplow, D. B. (2000) · Amyloid · doi:10.3109/13506120009146831 · Cited by 260
Human prion proteins expressed in Escherichia coli and purified by high‐affinity column refolding
Zahn, R., von Schroetter, C., & Wüthrich, K. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01330-6 · Cited by 253
Jones, E. M., & Surewicz, W. K. (2005) · Cell · doi:10.1016/j.cell.2005.01.034 · Cited by 250
Self-citationMembrane Environment Alters the Conformational Structure of the Recombinant Human Prion Protein
Morillas, M., Swietnicki, W., Gambetti, P., & Surewicz, W. K. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.52.36859 · Cited by 241
Self-citationHou, L., Kang, I., Marchant, R. E., & Zagorski, M. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200338200 · Cited by 218
Prion Diseases and Their Biochemical Mechanisms
Cobb, N. J., & Surewicz, W. K. (2009) · Biochemistry · doi:10.1021/bi900108v · Cited by 209
Self-citationIdentification of the Heparan Sulfate Binding Sites in the Cellular Prion Protein
Warner, R. G., Hundt, C., Weiss, S., & Turnbull, J. E. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110406200 · Cited by 205
Reliable determination of binding affinity and kinetics using surface plasmon resonance biosensors
Schuck, P. (1997) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(97)80074-2 · Cited by 176
Cell-surface prion protein interacts with glycosaminoglycans
Tao, P. A. N., Wong, B., Tong, L. I. U., Li, R., Petersen, R. B., & Sy, M. (2002) · Biochemical Journal · doi:10.1042/bj20020773 · Cited by 144
Mechanism of Chaperone Function in Small Heat Shock Proteins
Mchaourab, H. S., Dodson, E. K., & Koteiche, H. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206250200 · Cited by 113
PRNP Val129 homozygosity increases risk for early‐onset Alzheimer's disease
Dermaut, B., Croes, E. A., Rademakers, R., den Broeck, M. V., Cruts, M., Albert Hofman, D., van Duijn, C. M., & Broeckhoven, C. V. (2003) · Annals of Neurology · doi:10.1002/ana.10507 · Cited by 102
Prion protein codon 129 polymorphism and risk of Alzheimer disease
Riemenschneider, M. J., Klopp, N., Xiang, W., Wagenpfeil, S., Vollmert, C., Müller, U., Förstl, H., Illig, T., Kretzschmar, H. A., & Kurz, A. (2004) · Neurology · doi:10.1212/01.wnl.0000130198.72589.69 · Cited by 98
Prion protein and Alzheimer disease
Kellett, K. A. B., & Hooper, N. M. (2009) · Prion · doi:10.4161/pri.3.4.9980 · Cited by 88
Is indeed the prion protein a Harlequin servant of "many" masters?
Sorgato, M. C., Peggion, C., & Bertoli, A. (2009) · Prion · doi:10.4161/pri.3.4.10012 · Cited by 27
Cited by
Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons
Um, J. W., Nygaard, H. B., Heiss, J. K., Kostylev, M. A., Stagi, M., Vortmeyer, A., Wisniewski, T., Gunther, E. C., & Strittmatter, S. M. (2012) · Nature Neuroscience · doi:10.1038/nn.3178 · Cited by 662
Amyloid β Protein and Alzheimer’s Disease: When Computer Simulations Complement Experimental Studies
Nasica-Labouze, J., Nguyen, P. H., Sterpone, F., Berthoumieu, O., Buchete, N.-V., Coté, S., De Simone, A., Doig, A. J., Faller, P., Garcia, A., et al. (2015) · Chemical Reviews · doi:10.1021/cr500638n · Cited by 584
Um, J. W., Kaufman, A. C., Kostylev, M., Heiss, J. K., Stagi, M., Takahashi, H., Kerrisk, M. E., Vortmeyer, A., Wisniewski, T., Koleske, A. J., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.06.036 · Cited by 572
Viles, J. H. (2012) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2012.05.003 · Cited by 404
Williams, T. L., & Serpell, L. C. (2011) · The FEBS Journal · doi:10.1111/j.1742-4658.2011.08228.x · Cited by 335
Metadata
- Authors
- Chen, S., Yadav, S. P., & Surewicz, W. K.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2010-08
- Volume
- 285
- Issue
- 34
- Pages
- 26377-26383
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2016170408
- Cited by
- 289
- References
- 45
- FWCI
- 13.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.